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Table 1
Patient Characteristics HDT-ASCR n¼20 alloSCT n¼20
Median age in years (range) 51 (33-70) 55 (34-69)
Median number of previous
lines of therapy (range)
2 (2-4) 3 (2-7)
Chemosensitive 19/20 (95%) 20/20 (100%)
CR 8 7
PR 11 13
Median remission duration
(months) prior to
re-induction therapy
11.5 (0*-31) 5 (0*-12)
Remission duration  12 months
from re-induction therapy
11/20 (55%) 20/20 (100%)
* Denotes chemorefractory disease prior to re-induction.
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respectively, during the ﬁrst 30 days post HCT. Durable
chimerism was achieved in 45 (96%) patients. The cumula-
tive incidence of grade II-IV acute GVHD at day 100 was 12%
and extensive chronic GVHD at 1-yr was 36%. Non-relapse
mortality (NRM) at 3 years was 7%. The median follow up for
all patients was 1142 days and 1525 days (range; 365-3667)
for the 34 (72%) living patients. The 36-month probability of
progression free and overall survival (OS) was 40% and 79%
respectively. It is noteworthy that among the 23 patients
with progressive disease after TLI-ATG, 11 were returned to
durable (>1 year) complete remission without subsequent
relapse following a donor lymphocyte infusion or chemo-
radiotherapy. 13 patients died (relapse¼8 and other
causes¼5). Proportional hazards model showed improved
relapse free survival with higher CD3+ donor chimerism
(p¼0.01). We conclude that for patients with lymphoma
relapse after auto-HCT, allogeneic HCT from a sibling or
unrelated donor using TLI-ATG conditioning was a well
tolerated outpatient procedure, did not induce signiﬁcant
cytopenias and was associated with 3 year NRM of<10%. It is
unlikely that TLI-ATG conditioning itself provided long-term
lymphoma control in these heavily pre-treated patients, with
advanced disease. Rather the 79% 3-yr OS and the fact that
the majority of patients continue in durable CR suggest
retained graft antitumor reactions following TLI-ATG.82
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Introduction: Follicular lymphoma (FL) is an indolent non-
Hodgkin lymphoma characterized by high response rates
and long response duration(s) to therapy. In the relapsed/
refractory setting (rel/ref), high-dose therapy and autologous
stem cell rescue (HDT-ASCR) and non-myeloablative (NMA)
allogeneic stem cell transplantation (alloSCT) are deﬁnitive
therapies shown to provide long term disease free intervals.
To date, there remains an inherent difﬁculty in deciding the
appropriate consolidative transplant modality in rel/ref FL.
Therefore, we conducted an analysis of clinical features of FL
pts undergoing ﬁrst HDT-ASCR or alloSCT.
Methods: We retrospectively reviewed all pts with rel/ref FL
that proceeded to HDT-ASCR or NMA alloSCT at MSKCC
between 2006 and 2010. Chemosensitive disease was
deﬁned as a partial response (PR) or complete response (CR)
to the last treatment regimen prior to transplant by
computed tomography scans per IWG Criteria. Events were
deﬁned as progression of FL or death from any cause. Event-
free survival (EFS) and overall-survival (OS) were estimated
using Kaplan-Meier method.
Results: We identiﬁed 40 pts with rel/ref FL who had HDT-
ASCR (N¼20) or alloSCT (N¼20). Pts characteristics are out-
lined in the table below: The median follow-up for
survivors is 34 months. The estimated 3-year EFS and OS was60% and 62% with HDT-ASCR and 79% and 85% with alloSCT
respectively (p¼ns). FL pts with remission duration  12
months prior to re-induction therapy proceeding to con-
solidative HDT-ASCR had signiﬁcantly shorter EFS compared
to those pts with previous remission duration > 12 months
(P < 0.05, Figure 1). Furthermore, when HDT-ASCR and
alloSCT pts with a previous remission duration  12 months
prior to re-induction therapy were compared the estimated
3-year EFS was 79% for alloSCT and 36% for HDT-ASCR (P <
0.03). With relatively short follow-up, there was no differ-
ence in OS for these two groups.
Conclusion: The management of rel/ref FL remains a clini-
cally complex topic. In this exploratory analysis we demon-
strated that remission duration of  12 months prior to re-
induction chemotherapy is suggestive of inferior disease
control with HDT-ASCR. Longer follow-up is necessary to
determine the OS impact. Given the relatively unfavorable
pre-transplant characteristics of the alloSCT cohort, FL
appears to be exquisitely sensitive to an allogeneic effect.
Figure 1. EFS HDT-ASCR by Remission Duration to Re-induction.
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extranodal Non Hodgkin's lymphoma (NHL). Combination
chemotherapy followed by whole brain radiation has
remained the cornerstone of therapy. Relapse rates are
high and delayed neurotoxicity, with severe cognitive
dysfunction, is signiﬁcant. High dose chemotherapy fol-
lowed by autologous stem cell rescue has been used as
consolidation in newly diagnosed patients and as salvage
in times of relapse. This approach is considered
promising.
Methods: Between 2001 and 2012 we have treated 12
patients with CNS lymphoma (primary and secondary) with
high dose chemotherapy as primary consolidation therapy,
in lieu of radiation. All patients received “induction” with
a high dosemethotrexate containing regimen. Rituximabwas
used in 8 patients with B Cell NHL. Conditioning chemo-
therapy for trnaplant consisted of Thiotepa 300 mg/m2
(on Days -8 and -7), Busulfan (targeted to achieve an AUC of
5000 mMol x Min, as a single dose [from 2008] on days -6
through -3) and Cyclophosphamide 2000 mg/m2 on days -3
and -2. Prior to 2008 Busulfan was given at a dose of 0.8 mg/
kg q6h for 12 doses. One patient received BEAM for condi-
tioning. Stem cells reinfusion occurred on Day 0.Seizure
prophylaxis was with Clonazepam or phenytoin. Palifermin
was used for prophylaxis against mucositis. Granulocyte
Colony Stimulating Factor was administered from Day +6 to
facilitate count recovery.
Results: 12 patients with CNS lymphoma underwent an
autologous stem cell transplant as primary consolidation.
Median age at diagnosis was 56 (range 20-69). 10 patients
had Primary CNS lymphoma (9 with Diffuse Large B Cell
Lymphoma [DLCL] on morphology and 1 with T cell NHL
NOS), and 2 had secondary CNS lymphoma (1 with
Anaplastic Large Cell lymphoma and 1 with meningeal
relapse of DLCL). Median time to transplant was 8 months
(range 4-24 months). CSF involvement was present only in
the 2 patients with secondary CNS NHL. There were no
transplant related deaths. All patients developed mucositis,
but none required intubation. One patient relapsed during
conditioning therapy and was treated successfully with
radiation. No VOD or hemorrhagic cystitis was seen. There
was no delayed engraftment. Median follow-up post
transplant is 68.5 months (range 16-130 months). 11
patients are alive. One patient relapsed soon after trans-
plant but died 44 months later. The remaining 11 patients
continue to be in remission. 2 patients have returned to
college, 2 are gainfully employed and 3 are functioning
retirees.
Conclusion: High dose chemotherapy with Thiotepa-
Busulfan-Cyclophosphamide conditioning, is a highly effec-
tive consolidation therapy in patients with Primary CNS
lymphoma. No delayed neurotoxicity is seen. This approach
circumvents the toxicity of radiation, and may improve
survival and quality of life, a concept that will need to be
tested with a larger cohort.84
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Background: Depth of response to therapy in multiple
myeloma can be predictive of long term clinical outcomes.Various studies across the spectrum of myeloma patients
have indicated the prognostic signiﬁcance of attaining
a complete remission (CR). Normalization of serum free light
chains (FLC) may add to the sensitivity of assessing disease
response. Anecdotally, we have noted that patients in whom
the clonal or involved FLC not only normalizes but actually
suppresses below the uninvolved FLC seem to have superior
outcomes.We studied whether this depth of FLC suppression
was predictive of clinical outcomes in our post-transplant
cohort.
Methods: Records from 697 patients who underwent an
autologous stem cell transplant (ASCT) at our institution
from 1/2001-12/2011 were reviewed. All post-transplant
serum FLC values were reviewed. Patients were considered
to have a “suppressed” FLC if the clonal or involved FLC
reduced below the value of the uninvolved FLC within 12
months of their transplant. Duration of suppression was
assessed based on follow up serum FLC measurements. Time
to progression (TTP) and overall survival (OS) based on depth
of FLC suppression were calculated using Kaplan-Meir
analysis.
Results: All patients were treated with high dose melphalan
followed by an ASCT. Median age at the time of ASCT was 60
years (range 35-76) with median time from diagnosis to
ASCT of 7 months (range 2-196 months). With a median
follow up time of 5.9 years, 385 (55%) were alive at time of
analysis and 463 (66%) had relapsed. Median TTP for the
entire cohort was 26 months (95% CI; 24-30 months). 246
patients had at least one time when their involved FLC
suppressed below the uninvolved FLC after ASCT. The
median TTP was 36 months for patients with a suppressed
FLC compared with 19 months (P < 0.0001) for the rest.
Median OS was 6.5 years vs. 4.7 years for those in whom the
involved FLC did and did not suppress once respectively
(p¼0.0013). Duration of FLC suppression was signiﬁcantly
associated with superior outcomes. For those patients
whose FLC remained suppressed on at least three consec-
utive occasions, median TTP was not reached compared
with 21 months (P < 0.0001). Similarly, median OS was
superior for patients with sustained FLC suppression;
median OS not reached vs. 4.9 years for unsuppressed
patients (P < 0.0001, Figure 1). These observed improve-
ments in clinical outcomes were independent of attainment
of a CR.
Conclusions: Suppression of the involved FLC below the
uninvolved FLC is associated with superior TTP and OS in
myeloma patients treated with an ASCT. Beyond the level of
suppression, the duration of suppression is also highly
associated with superior outcomes independent of attain-
ing a complete response. Depth of treatment response to
ASCT when measured by sustained FLC suppression can
identify patients who will experience long term disease
control.
Figure 1.
